Effects of an Immunosuppressive Treatment in the GRMD Dog Model of Duchenne Muscular Dystrophy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Barthélémy, Inès ^a   Uriarte, Ane ^a   Drougard, Carole ^a   Unterfinger, Yves ^a   Thibaud, Jean Laurent ^a   Blot, Stéphane ^a  

^a UNIVERSITÉ PARIS EST   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CYCLOSPORIN A; DYSTROPHIN; PREDNISOLONE;

ACCELEROMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; EVALUATION RESEARCH; EXPERIMENTAL DOG; GAIT; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ISOMETRICS; MOTOR PERFORMANCE; NONHUMAN; PARAMETRIC TEST; TREATMENT DURATION;

ACCELEROMETRY; ANIMALS; BIOMECHANICS; CREATINE KINASE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOGS; FOLLOW-UP STUDIES; GAIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PRINCIPAL COMPONENT ANALYSIS; TETANY;

ANIMALIA; CANIS FAMILIARIS;

EID: 84869753567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048478     Document Type: Article

References (43)

1. Yiu EM, Kornberg AJ, (2008) Duchenne muscular dystrophy. Neurol India 56: 236-247.
2. Valentine BA, Cooper BJ, de LA, O'Quinn R, Blue JT, (1988) Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 88: 69-81.
3. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA, (2009) Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19: 241-249.
4. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, et al. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65: 667-676.
5. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, et al. (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444: 574-579.
6. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, et al. (2010) Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 120: 1140-1150.
7. Rouger K, Larcher T, Dubreil L, Deschamps JY, Le GC, et al. (2011) Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs. Am J Pathol 179: 2501-2518.
8. Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, et al. (2003) Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 10: 750-757.
9. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, et al. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15: 1160-1166.
10. Howell JM, Lochmuller H, O'Hara A, Fletcher S, Kakulas BA, et al. (1998) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 9: 629-634.
11. Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, et al. (2007) Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14: 1249-1260.
12. Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, et al. (2004) Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood 104: 4311-4318.
13. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R, (2007) Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 119: e320-e324.
14. Wong BL, Christopher C, (2002) Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 17: 183-190.
15. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, et al. (2003) Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27: 222-227.
16. Pradhan S, Ghosh D, Srivastava NK, Kumar A, Mittal B, et al. (2006) Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253: 1309-1316.
17. Markham LW, Kinnett K, Wong BL, Woodrow BD, Cripe LH, (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18: 365-370.
18. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, et al. (1997) Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 20: 469-478.
19. Sharma KR, Mynhier MA, Miller RG, (1993) Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 43: 527-532.
20. Kirschner J, Schessl J, Schara U, Reitter B, Stettner GM, et al. (2010) Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol.
21. Bretag AH, (2007) Stem cell treatment of dystrophic dogs. Nature 450: E23-E25.
22. Liu JM, Okamura CS, Bogan DJ, Bogan JR, Childers MK, et al. (2004) Effects of prednisone in canine muscular dystrophy. Muscle Nerve 30: 767-773.
23. Bartlett RJ, Winand NJ, Secore SL, Singer JT, Fletcher S, et al. (1996) Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res 57: 650-654.
24. Lennon TP, Yee GC, Kennedy MS, Torok-Storb B, Burstein SA, et al. (1987) Monitoring of cyclosporine therapy with in vitro biological assays. Transplantation 44: 799-804.
25. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG, (2001) Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98: 235-243.
26. Barthelemy I, Thibaud JL, Vulin A, Bertoldi D, Goyenvalle A, et al. (2007) Functional evaluation of dystrophic dogs treated by exon-skipping. Neuromuscul Disord 17: 898.
27. Thibaud JL, Monnet A, Bertoldi D, Barthelemy I, Blot S, et al. (2007) Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul Disord 17: 575-584.
28. Barthelemy I, Barrey E, Thibaud JL, Uriarte A, Voit T, et al. (2009) Gait analysis using accelerometry in dystrophin-deficient dogs. Neuromuscul Disord 19: 788-796.
29. Barthelemy I, Barrey E, Aguilar P, Uriarte A, Le CM, et al. (2011) Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskelet Disord 12: 75.
30. Marsh AP, Eggebeen JD, Kornegay JN, Markert CD, Childers MK, (2010) Kinematics of gait in golden retriever muscular dystrophy. Neuromuscul Disord 20: 16-20.
31. Sharma KR, Mynhier MA, Miller RG, (1995) Muscular fatigue in Duchenne muscular dystrophy. Neurology 45: 306-310.
32. Nicolas-Metral V, Raddatz E, Kucera P, Ruegg UT, (2001) Mdx myotubes have normal excitability but show reduced contraction-relaxation dynamics. J Muscle Res Cell Motil 22: 69-75.
33. Alderton JM, Steinhardt RA, (2000) Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. J Biol Chem 275: 9452-9460.
34. Metzinger L, Passaquin AC, Leijendekker WJ, Poindron P, Ruegg UT, (1995) Modulation by prednisolone of calcium handling in skeletal muscle cells. Br J Pharmacol 116: 2811-2816.
35. Valentine BA, Cooper BJ, Cummings JF, de LA, (1990) Canine X-linked muscular dystrophy: morphologic lesions. J Neurol Sci 97: 1-23.
36. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, et al. (1998) A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 12: 2499-2509.
37. Giger JM, Haddad F, Qin AX, Baldwin KM, (2004) Effect of cyclosporin A treatment on the in vivo regulation of type I MHC gene expression. J Appl Physiol 97: 475-483.
38. Webster C, Silberstein L, Hays AP, Blau HM, (1988) Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52: 503-513.
39. Michel RN, Dunn SE, Chin ER, (2004) Calcineurin and skeletal muscle growth. Proc Nutr Soc 63: 341-349.
40. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, et al. (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148: 452-460.
41. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, et al. (2003) Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285: E363-E371.
42. Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, et al. (2007) Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 16: 563-577.
43. Banks GB, Chamberlain JS, (2008) The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84: 431-453.